Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Wednesday. The brokerage issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Down 1.9 %

CTSO opened at $1.02 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The stock has a market capitalization of $55.77 million, a P/E ratio of -2.83 and a beta of 0.78. The business has a 50 day simple moving average of $1.07 and a 200-day simple moving average of $1.05.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Cytosorbents during the fourth quarter worth $30,000. Renaissance Technologies LLC boosted its position in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp boosted its position in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after buying an additional 16,701 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Cytosorbents in the 4th quarter valued at about $99,000. Finally, Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.